Suspended

Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Digestive System Diseases+11

+ Fatty Liver

+ Lipid Metabolism, Inborn Errors

From 18 to 80 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Observational
See protocol details

Summary

Principal SponsorAssy Nimer
Study ContactNimer Assy, MMore contacts
Last updated: February 15, 2013
Sourced from a government-validated database.Claim as a partner

Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity. Morbidity rates are estimated at 20% to 30% in Western adults, increasing to 90% in patients who are morbidly obese or diabetic. Risk factors in non-obese NAFLD patients are of especial practical and theoretical importance. Cholesterol Ester Storage Disease (CESD) is an autosomal recessive chronic disease of variable phenotype, caused by a deficiency in lysosomal acid lipase (LAL) and characterized by accumulation of fat in tissues and organs. Hepatic accumulation of fat in this disorder can cause hepatomegaly with varying degrees of damage varying from steatosis to fibrosis, elevated aminotransaminases, and isolated splenomegaly. Since the contribution of LAL deficiency to non-obese NAFLD is poorly understood, the investigators propose to evaluating the association between NAFLD and LAL deficiency in a prospective study in our population.

Principal SponsorAssy Nimer
Study ContactNimer Assy, MMore contacts
Last updated: February 15, 2013
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Digestive System DiseasesFatty LiverLipid Metabolism, Inborn ErrorsLipidosesLiver DiseasesMetabolic DiseasesMetabolism, Inborn ErrorsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNutritional and Metabolic DiseasesLysosomal Storage DiseasesGenetic Diseases, InbornLipid Metabolism DisordersCholesterol Ester Storage DiseaseNon-alcoholic Fatty Liver Disease

Criteria

3 inclusion criteria required to participate
Age between 18-80 years

BMI 25-40

Fatty liver disease (bright liver, hepatomegaly by ultrasound (Liver span > 15 cm mid clavicle line), splenomegaly ( > 13 cm) or both

9 exclusion criteria prevent from participating
Alcohol abuse > 30 gm/day, or > 70 gram per week

Autoimmune hepatitis

Biliary liver disease

Chronic hepatitis (B and C)

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Assy Nimer

Safed, IsraelOpen Assy Nimer in Google Maps
SuspendedOne Study Center